Compare Sanofi SA (SNY) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Unity Software Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Unity Software Inc trades at $29.78 (market cap $13.01B). The key difference: Sanofi SA is far larger — about 8.1× Unity Software Inc's market cap, and Sanofi SA pays a 5.5% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| SNY | U | |
|---|---|---|
Market Cap | $104.83B | $13.01B |
Sector | Health | Technology |
52-Week High | $52.34 | $49.47 |
52-Week Low | $41.33 | $17.13 |
Enterprise Value | $121.32B | $13.11B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Unity Software (U) trades at $29.87, up 3.04% today, showing bullish technical momentum above key support levels. The company maintains strong revenue of $1.85B with improving gross margins at 62.79%, though net losses persist at -$402.77M. Recent Unity 7 platform announcements and AI integration focus signal strategic growth initiatives. Analyst consensus remains strongly bullish with 69% buy ratings and $36.50 price target, representing 22% upside potential from current levels.
Unity presents a growth opportunity with improving financial trends and strong institutional support, but faces execution risks in profitability turnaround. The stock's elevated valuation multiples (P/S 6.61, EV/EBITDA 134.62) require sustained revenue growth justification. Near-term catalyst includes Q2 2026 earnings on August 5, where analysts expect EPS of $0.24 after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
